Biotech's had a rough run.
Last September Democratic candidate Hillary Clinton tweeted that if elected, she would take on drug-price hikes.
Her tweet sent the sector tumbling, and while there have been periods of recovery, the sector is down 20% year-to-date.
With a Clinton victory looking more likely, and the possibility of a Democratic Congress, the last few days have not been pretty for health care.
The "Halftime Report" experts and Raymond James' senior biotech analyst discussed if the dip presents a buying opportunity, or if these names have further still to fall.